Abstract
Phosphoinositide 3-kinases (PI3Ks) play an essential role in the intracellular signal transduction cascades initiated by the activation of cell surface receptors through their specific extracellular signals. PI3Ks control a variety of cellular responses, including growth, protection from apoptosis, motility, metabolism and intracellular protein sorting. Eight catalytic PI3K isoforms exist in human, which are grouped into three classes (I-III), based on structural homology and in vitro substrate specificity. Class I PI3Ks mediate signalling by receptor tyrosine kinases (RTKs) and G-proteincoupled receptors (GPCRs). The class II of PI3Ks, which comprises three distinct isoforms (PI3KC2α, PI3KC2β and PI3KC2γ) are less well characterized in terms of cellular functions. PI3KC2α and PI3KC2β are activated downstream of RTKs and GPCRs and play a role in cell migration, survival, glucose transport and endocytosis. Recently, the first isoform-specific small molecule inhibitors of PI3KC2β were described and evaluated as anti-proliferative agents in cancer. In this review, we will discuss the different regulatory mechanisms and functions of class II PI3Ks in the context of cell surface receptor signalling and their potential as novel drug targets in the field of oncology.
Keywords: Cancer, cell migration, G-protein-coupled receptor, phosphoinositide 3-kinase, receptor tyrosine kinase.
Current Signal Transduction Therapy
Title:Class II Phosphoinositide 3-Kinases as Potential Novel Drug Targets
Volume: 8 Issue: 2
Author(s): Alexandre Arcaro, Anna Borgstrom and Karolina Blajecka
Affiliation:
Keywords: Cancer, cell migration, G-protein-coupled receptor, phosphoinositide 3-kinase, receptor tyrosine kinase.
Abstract: Phosphoinositide 3-kinases (PI3Ks) play an essential role in the intracellular signal transduction cascades initiated by the activation of cell surface receptors through their specific extracellular signals. PI3Ks control a variety of cellular responses, including growth, protection from apoptosis, motility, metabolism and intracellular protein sorting. Eight catalytic PI3K isoforms exist in human, which are grouped into three classes (I-III), based on structural homology and in vitro substrate specificity. Class I PI3Ks mediate signalling by receptor tyrosine kinases (RTKs) and G-proteincoupled receptors (GPCRs). The class II of PI3Ks, which comprises three distinct isoforms (PI3KC2α, PI3KC2β and PI3KC2γ) are less well characterized in terms of cellular functions. PI3KC2α and PI3KC2β are activated downstream of RTKs and GPCRs and play a role in cell migration, survival, glucose transport and endocytosis. Recently, the first isoform-specific small molecule inhibitors of PI3KC2β were described and evaluated as anti-proliferative agents in cancer. In this review, we will discuss the different regulatory mechanisms and functions of class II PI3Ks in the context of cell surface receptor signalling and their potential as novel drug targets in the field of oncology.
Export Options
About this article
Cite this article as:
Arcaro Alexandre, Borgstrom Anna and Blajecka Karolina, Class II Phosphoinositide 3-Kinases as Potential Novel Drug Targets, Current Signal Transduction Therapy 2013; 8 (2) . https://dx.doi.org/10.2174/15743624113086660002
DOI https://dx.doi.org/10.2174/15743624113086660002 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Circular RNAs and Glioma: Small Molecule with Big Actions
Current Molecular Medicine Glimpse into the Cellular Internalization and Intracellular Trafficking of Lipid- Based Nanoparticles in Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Using the Neurosphere Assay to Quantify Neural Stem Cells In Vivo
Current Pharmaceutical Biotechnology An In Silico Appraisal of Azoic and Disulphide Derivatives for Anticancer Activity Against HPV E6 Oncoprotein to Medicate Cervical Cancer
Combinatorial Chemistry & High Throughput Screening The Role of STAT3 Signaling in Mediating Tumor Resistance to Cancer Therapy
Current Drug Targets Modulation of the Cell Cycle and Induction of Apoptosis in Human Cancer Cells by Synthetic Bile Acids
Current Cancer Drug Targets Gestational Trophoblastic Neoplasia, an Ancient Disease: New Light and Potential Therapeutic Targets
Anti-Cancer Agents in Medicinal Chemistry Review of the Phytochemistry and Biological Activity of Cissus incisa Leaves
Current Topics in Medicinal Chemistry Epothilones: A Novel Class of Non-taxane Microtubule-stabilizing Agents
Current Pharmaceutical Design Prognostic and Therapeutic Implications of MicroRNA in Malignant Pleural Mesothelioma
MicroRNA Solid Lipid Nanoparticles: A Promising Nanomaterial in Drug Delivery
Current Pharmaceutical Design Evidence for Epigenetic Alterations in Turner Syndrome Opens up Feasibility of New Pharmaceutical Interventions
Current Pharmaceutical Design Design of Oleanolic Acid-based Hybrid Compounds as Potential Pharmaceutical Scaffolds
Letters in Drug Design & Discovery Luteolin, a Flavonoid with Potential for Cancer Prevention and Therapy
Current Cancer Drug Targets Oncolytic Virus Therapy - Foreword
Current Cancer Drug Targets Applications of HPLC-MALDI-TOF MS/MS Phosphoproteomic Analysis in Oncological Clinical Diagnostics
Current Proteomics Polyphenols as Potential Therapeutics for Pain and Inflammation in Spinal Cord Injury
Current Molecular Pharmacology Alphaviruses and their Derived Vectors as Anti-Tumor Agents
Current Cancer Drug Targets Electroporation: An Effective Method For <i>In Vivo</i> Gene Delivery
Drug Delivery Letters Cell Death in Mammalian Development
Current Pharmaceutical Design